learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
5 / 801 resultslearn Setipiprant
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn retinoic acid
learn myristoyl pentapeptide-17
Research
5 / 1000+ results
research Complications of Cushing's syndrome: state of the art
Cushing's syndrome can cause serious health problems, and early treatment is crucial, but some issues may remain after treatment.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research An integrative view of mammalian seasonal neuroendocrinology
The article concludes that better understanding gene regulation related to seasonal changes can offer insights into the mechanisms of seasonal timing in mammals.
research Nanoparticles in Cancer Treatment: A Narrative Review
Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.
research Assessment of the Ability of the ChatGPT-5 Model to Pass the Endocrinology Specialization Exam
ChatGPT-5 can pass the endocrinology exam but isn't fully reliable for clinical decisions yet.
Community Join
5 / 1000+ resultscommunity pyrilutamide phase 2 results right here, thanks to user Glaringbooch
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community pyrilutamide solution progress log
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
community Potentially Positive Pyrilutamide News Coming
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.